Kaida BioPharma
Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing KAD-101, a novel prolactin receptor antagonist targeting recurrent ovarian cancer in patients with limited durable treatment options. The company is advancing KAD-101 toward first-in-human clinical evaluation.
- Company typePrivate
- Founded2022
- HeadquartersFort Lauderdale, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kaida BioPharma does
Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing targeted anti-cancer therapies for treatment-resistant gynecological cancers. Founded in 2022 and headquartered in Fort Lauderdale, Florida, the company is focused on what it terms the "ovarian cancer gap" — patients with recurrent ovarian cancer who have exhausted standard-of-care therapies and have limited durable treatment options. The company operates with 1-10 employees and is privately funded.
Kaida's sole disclosed product candidate is KAD-101, a novel prolactin receptor antagonist that targets prolactin receptor signaling pathways implicated in ovarian cancer progression. The mechanism of action is distinct from standard ovarian cancer treatments, positioning KAD-101 as a differentiated therapeutic approach for the recurrent setting. As of the available data, KAD-101 remains in preclinical development and is being advanced toward first-in-human clinical evaluation. The company has assembled an executive leadership team with experience in clinical development, regulatory affairs, manufacturing, and commercial strategy to support this transition, with Dr. Stella Vnook appointed Acting CEO and Chairperson.
Kaida BioPharma is currently pre-revenue with no commercial products, pricing structures, or distribution channels established. The company raised approximately $1.57M in an early-stage funding round in January 2026 (lead investor undisclosed). Its anticipated future revenue model centers on drug commercialization post-regulatory approval, likely through one-time licensing arrangements and prescription sales via specialty pharmacy channels and hospital formularies. Current go-to-market activity is focused on building relationships with academic medical centers, key opinion leaders, and oncology-focused healthcare institutions to support clinical development partnerships. The company has generated regional visibility through semi-finalist selection in the BIOPITCH competition at the Florida Innovation Conference and finalist selection in the Tampa Tank Pitch Competition, both in November 2025.
Kaida BioPharma firmographics
Firmographics- Name
- Kaida BioPharma
- Legal name
- Kaida BioPharma
- Website
- https://kaida-biopharma.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Kaida BioPharma is an early-stage, privately-held pharmaceutical company developing KAD-101, a novel prolactin receptor antagonist targeting recurrent ovarian cancer in patients with limited durable treatment options. The company is advancing KAD-101 toward first-in-human clinical evaluation.
- Ownership category
- akta.pro rank
Kaida BioPharma industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Kaida BioPharma is headquartered
LocationHeadquarters
- HQ city
- Fort Lauderdale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kaida BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Drug Development and Commercialization: As an early-stage pharmaceutical company, Kaida BioPharma is pre-revenue and focused on advancing KAD-101 through clinical development. Revenue generation is anticipated through eventual drug commercialization upon regulatory approval, likely via prescription sales through specialty pharmacy channels and hospital formularies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Kaida BioPharma product offering
Product offeringCore offering
Kaida BioPharma is developing KAD-101, a novel prolactin receptor antagonist candidate intended for the treatment of recurrent ovarian cancer. The company is advancing KAD-101 through preclinical development toward first-in-human clinical evaluation, targeting patients with limited durable treatment options within the 'ovarian cancer gap.' Revenue generation is anticipated through eventual drug commercialization following regulatory approval.
Product overview
Kaida BioPharma is an early-stage pharmaceutical company developing targeted anti-cancer therapies. The company's primary focus is KAD-101, a prolactin receptor antagonist, as its lead product candidate for treating recurrent ovarian cancer. The company is building an executive team to advance this candidate toward first-in-human clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- KAD-101 KAD-101 is the lead prolactin receptor antagonist candidate developed for the treatment of recurrent ovarian cancer in patients with limited durable treatment options. It is currently advancing through preclinical development toward first-in-human clinical evaluation.
Companies that use Kaida BioPharma
Customer profileSegments1 record
Ideal customer profiles1 record
Kaida BioPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Kaida BioPharma partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Kaida BioPharma competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: AstraZeneca markets Lynparza (olaparib), the leading PARP inhibitor approved for recurrent ovarian cancer. Broad incumbent defining the standard of care in the indication Kaida is targeting, and a likely strategic partner or acquirer of differentiated mechanisms.
- GSK (Tesaro legacy): GSK acquired Tesaro and commercializes Zejula (niraparib), a PARP inhibitor approved for recurrent ovarian cancer. Broad incumbent competitor in the recurrent ovarian cancer treatment landscape, with established commercial infrastructure Kaida will ultimately contend with.
Direct peers
- Clovis Oncology: Clovis developed and commercialized Rubraca (rucaparib), a PARP inhibitor for recurrent ovarian cancer. Direct comparable in targeting recurrent ovarian cancer with a novel mechanism, though at a more advanced commercial stage.
- Aprea Therapeutics: Aprea is a clinical-stage oncology company developing therapeutics for ovarian and other cancers. Comparable as a small-cap biotech focused on innovative mechanisms targeting recurrent ovarian cancer, similar in scale and clinical positioning.
- Mersana Therapeutics: Mersana is developing antibody-drug conjugates for ovarian cancer and other oncology indications. Comparable as a clinical-stage biotech focused on novel cytotoxic approaches for recurrent ovarian cancer, similar in stage and therapeutic theme to Kaida.
- ImmunoGen (now part of AbbVie): ImmunoGen developed Elahere (mirvetuximab soravtansine), an ADC approved for recurrent ovarian cancer. Direct comparable in the recurrent ovarian cancer space where Kaida is positioning KAD-101, with overlap in patient population and targeting treatment-resistant disease.
Emerging players
- Cardiff Oncology: Cardiff Oncology is a clinical-stage biotech developing small-molecule oncology therapies. Comparable as a similarly small, publicly-listed emerging oncology biotech focused on novel mechanisms, providing a relevant benchmark for stage and capital profile.
- Anixa Biosciences: Anixa Biosciences is a small clinical-stage biotech pursuing novel oncology therapeutics, including in hormone-driven cancers. Comparable in scale and as an emerging oncology player exploring novel hormone-receptor-adjacent mechanisms, similar to Kaida's prolactin receptor approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Kaida BioPharma social profiles
Digital presenceKaida BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kaida BioPharma leadership team
Management profileNumber of profiles
Profiles2 records
Kaida BioPharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kaida BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kaida BioPharma
What does Kaida BioPharma do?
Kaida BioPharma is developing KAD-101, a novel prolactin receptor antagonist candidate intended for the treatment of recurrent ovarian cancer. The company is advancing KAD-101 through preclinical development toward first-in-human clinical evaluation, targeting patients with limited durable treatment options within the 'ovarian cancer gap.' Revenue generation is anticipated through eventual drug commercialization following regulatory approval.
Is Kaida BioPharma a public or private company?
Kaida BioPharma is a private company. It is classified as unknown and is currently operating.
When was Kaida BioPharma founded?
Kaida BioPharma was founded in 2022. It employs 1 to 10 people.
Where is Kaida BioPharma based?
Kaida BioPharma is headquartered in Fort Lauderdale, United States, in the North America region.
How does Kaida BioPharma make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Who are Kaida BioPharma's main competitors?
Broad incumbents on record are AstraZeneca and GSK (Tesaro legacy). Direct peers are Clovis Oncology, Aprea Therapeutics, Mersana Therapeutics and ImmunoGen (now part of AbbVie). Emerging players are Cardiff Oncology and Anixa Biosciences.
Does Kaida BioPharma have an API?
No public API is recorded for Kaida BioPharma.
What industry is Kaida BioPharma in?
Kaida BioPharma's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 32541 and its SIC code is 2834.